Loading stock data…
BioNTech SE (BNTX)
$89.33-2.73 (-2.97%)
Market ClosedLast close Jul 24
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioNTech SE in the Healthcare sector is trading at $89.33 with a market capitalization of $22.8B. Wall Street consensus targets $121.58 (20 analysts), implying a +36.1% move over the next 12 months. The stock is currently 28% below its 52-week high of $124.00, remaining 9.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +36.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $118.10M↓ | $907.40M↓ | $1.52B↑ | $260.80M↑ | $182.80M |
| Gross Profit | $46.70M↓ | $574.10M↓ | $1.37B↑ | $184.40M↑ | $99.00M |
| Operating Income | -$671.20M↓ | -$280.50M↓ | $653.90M↑ | -$478.50M↑ | -$561.50M |
| Net Income | -$531.90M↓ | -$305.00M↓ | -$28.70M↑ | -$386.60M↑ | -$415.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.70%
Volume
Today's trading volume
886,017
Recent News
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
European equities traded in the US as American depositary receipts were tracking higher late Friday
Is BioNTech (BNTX) Undervalued As It Exits German Manufacturing Sites?
BioNTech (NasdaqGS:BNTX) is in focus after management moved to exit certain German manufacturing sites, a shift that could reshape the company’s cost structure while raising questions around future capacity and operational execution. See our latest analysis for BioNTech. At a share price of $92.98, BioNTech has seen its 1 month share price return rise 7.49%, although the year to date share price return is down 3.84% and the 5 year total shareholder return has declined 57.54%. This suggests...
BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump
BioNTech’s share price has declined about 57.5% over the past five years, and with the stock closing at US$92.98 and screening as overvalued on market multiples, the key issue is whether the recent pricing still leaves enough upside to justify the risk. BioNTech’s share price has fallen roughly 57.5% over five years, which indicates that long term shareholders have faced a steep reset in expectations. Ongoing plans to exit certain German manufacturing sites may help tighten the company’s...
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th
Former Pfizer Building Is Crumbling—Just as the Stock Has
Construction at Pfizer’s former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues. The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the index, at more than 7%. Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.